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INTRODUCTION 
Lung cancer is the leading cause of cancer mortality world-
wide, and non-small cell lung cancer (NSCLC) accounts for 
85% of its diagnoses [1]. Despite paradigm shifting targeted 
(personalized/precision) opportunities for a select group of 
patients, current treatments have failed to improve the five-
year survival rate of only 16.3% [2]. Enhancing the host 
immune systems’ ability to combat NSCLC has been an 
unrealized goal for decades. 
Conventional radiotherapy and chemotherapy have a low 
therapeutic window, causing detrimental effects to both tumor 
and healthy cells alike. Furthermore, an increasing level of 
immunosuppressive regulatory cells in the tumor 
microenvironment and inadequate cytotoxic T-lymphocytes 
mediated anti-tumor activity characterize tumor progression, 
making the enhancement of the host immune system’s ability 
to combat NSCLC crucial
 
[3]. With recent studies indicating 
sunitnib’s role in inhibiting immunosuppressive cells in the 
tumor microenvironment and reovirus’ oncolytic, 
immunostimulating properties in targeting tumor cells, this 
investigation aims to explore the potential of combining 
reovirus and sunitnib as a novel therapy for NSCLC [4]. 
 
METHODS 
Reovirus and sunitnib effective dose 50 (ED50) were 
determined for human NSCLC cell lines A549, H460, H1299, 
and H1975 by exposing each to varying concentrations of 
reovirus or sunitnib for 48 hours, and quantifying absorbance 
with WST-1 reagent at 450nm. % viability was used to 
generate dose response curves, and Calcusyn software was 
utilized to calculate ED50. Each cell line was then exposed to 
reovirus, sunitnib, or combination at ED50, ½ ED50, or ¼ 
ED50 for 48 hours. 20µM was used as ED50 for sunitnib 
resistant cell lines. Absorbance at 450nm upon WST-1 
exposure was read, and combination index (CI) was calculated 
using Calcusyn. Each experiment contained at least 3 
replicates and was repeated 3 times. CI<1 indicates synergistic 
effects, CI=1 indicates additive effects, and CI>1 indicates 
antagonistic effects. 
 
 
RESULTS 
Reovirus and sunitnib ED50 values for A549, H460, H1299, 
and H1975 cells were 15.29±0.99MOI and 17.12±2.62µM, 
238.02±41.29MOI and 11.27±1.52µM, 6.85±2.39MOI and 
resistant, and 19.80±20.35µM and not determinable, 
respectively. CI values for all cell lines were < 1at ED50. 
 
DISCUSSION AND CONCLUSIONS 
In the present in vitro study, we have demonstrated that 
sunitnib and reovirus combination therapy results in synergy 
in NSCLC cells. This promising investigation establishes the 
preclinical foundation for further investigations into reovirus 
and sunitnib as a novel combination therapy to treat NSCLC. 
Following ex vivo and in vivo investigations, it is anticipated 
that this study will culminate into a human clinical trial.    
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